Solid IO welcomes new international investors

"Beyond capital, we were looking for partners who understand the complexity of healthcare innovation, share our long-term vision, and can help us build a globally relevant company. We believe Leo Capital and Life Science Invest are a strong fit for us as we prepare for the next stage of growth, and we warmly welcome them as part of the Solid IO story," says Noora Hujala, CEO and co-founder of Solid IO.

"Solid IO combines world-class Finnish science, clear clinical relevance, and long-term platform potential in immuno-oncology, with the ambition to build a globally relevant company -  exactly the kind of team we are excited to back. We’re excited to support Noora and the team in the next phase of growth," says Olga Balakina, Vice President at Leo Capital.

"Solid IO is addressing a huge gap in immuno-oncology with a differentiated technology platform, strong scientific foundation and a world class team. Solid IOs technology meet a significant clinical need and in parallel providing a tool to accelerate drug development. On top of this there is a vast long term value in the unique data generated through the platform," says Kristofer Klerfalk, Manager Partner of Life Science Invest.

Since its spinout from the University of Helsinki in 2025, Solid IO has secured €2 million in total funding.

‍

Read and hear more here.

‍